Pitavastatin approved for treatment of primary hypercholesterolemia and combined yslipidemia

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 997-1005

  Sasaki, Jun ^a  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Europe; Japan; Korea; Randomized clinical trial; Thailand

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; COMBINED DYSLIPIDEMIA; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EUROPE; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; JAPAN; KOREA; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; THAILAND; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE III AS TOPIC; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; PYRROLES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80051881787     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S7802     Document Type: Review

References (53)

1. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy- 3-methylglutaryl coenzyme A reductase by ML-236 A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72(2):323-326.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex CAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
6. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
7. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol. 2007;60(8):812-818.
8. Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006;23(3):506-512.
9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-581.
10. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet)- LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther. 2008;36(8):709-731.
11. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921-936.
12. Jadhav SB, Jain GK. Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol. 2006;58(1):3-18.
13. Kajinami K, Mabuchi H, Saito Y. NK-104: A novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs. 2000; 9(11):2653-2661.
14. McKenney JM. New cholesterol guidelines, new treatment challenges. Pharmacotherapy. 2002;22(7):853-863.
15. Nozue T, Yamamoto S, Tohyama S, et al. Kanagawa PTCA Conference Study Group. Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): Rationale and design. Circ J. 2009;73(2):352-355.
16. Miyauchi K, Kimura T, Morimoto T, et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and design. Circ J. 2006;70(12):1624-1628.
17. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J. 2009;73(2):361-370.
18. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis. 2004;174(2):253-259.
19. Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. J Clin Pharmacol. 2009;49(5):568-573.
20. Di B, Su MX, Yu F, et al. Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;868(1-2):95-101.
21. Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008;18(5):424-433.
22. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60(5):494-497.
23. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005;78(4):342-350.
24. Sakamoto T, Kojima S, Ogawa H, et al; MUSASHI-AMI Investigators. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI. Circ J. 2007;71(9):1348-353.
25. Ono K, Kawasaki M, Tanaka R, et al. Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: Effect of pitavastatin therapy. Ultrasound Med Biol. 2009;35(2):193-200.
26. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J. 2008;72(4): 538-544.
27. Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-138.
28. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol. 2006;26(1):82-86.
29. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11):2728-2732.
30. Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura K, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J. 2010;74(1):195-202.
31. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy- 3-methylglutarylcoenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009; 16(5):539-545.
32. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a independent manner. Pharmacol Res. 2010;61(1):58-61.
33. Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20(1):16-22.
34. Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51(4):365-371.
35. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the doubleblind, three-group parallel comparison. Arzneimittelforschung. 2002;52(4):251-255.
36. Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: Results of a 12-week, open label study. J Atheroscler Thromb. 2006;13(2):108-113.
37. Nozue T, Michishita I, Ito Y, Hirano T. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2008;15(3):146-153.
38. Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: Results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731-739.
39. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-1101.
40. Hiro T, Kimura T, Morimoto T, et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293-302.
41. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J. 2009;73(8):1466-1472.
42. Sansanayudh N, Wongwiwatthananukit S, Putwai P, Dhumma- Upakorn R. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother. 2010;44(3):415-423.
43. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008; 201(2):345-352.
44. Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365-2373.
45. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162(2):373-379.
46. Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27(7):1074-1082.
47. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11): 2755-2764.
48. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. J Clin Lipidol. 2009;4(3):291-302.
49. Hounslow NJ. Efficacy and safety of pitavastatin compared to pravastatin in elderly patients with primary hypercholesterolemia or combined dyslipidemia. J Clin Lipidol. 2007;1(5):439.
50. Teramoto T, Saito Y, Yamada N, et al. Clinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia- results of a multicenter long-term study. J Clin Therap Med. 2001;17(6):885-913. Japanese.
51. Noji Y, Higashikata T, Inazu A, et al; Hokuriku NK-104 Study Group. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163(1):157-164.
52. Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16(5): 654-661.
53. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210(1):202-208.